Format

Send to

Choose Destination
Rheumatol Int. 2018 Apr;38(Suppl 1):163-169. doi: 10.1007/s00296-018-3948-x. Epub 2018 Apr 7.

The Estonian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR).

Author information

1
Department of General Pediatrics and Neurology, Tartu University Hospital, Children's Clinic, Lunini 6, 51014, Tartu, Estonia. Chris.Pruunsild@kliinikum.ee.
2
Department of General Pediatrics and Neurology, Tartu University Hospital, Children's Clinic, Lunini 6, 51014, Tartu, Estonia.
3
Clinica Pediatrica e Reumatologia, Paediatric Rheumatology International Trials Organisation (PRINTO), Istituto Giannina Gaslini, Via Gaslini 5, 16147, Genoa, Italy.
4
Dipartimento di Pediatria, Università di Genova, Genoa, Italy.
5
Clinica Pediatrica e Reumatologia, Paediatric Rheumatology International Trials Organisation (PRINTO), Istituto Giannina Gaslini, Via Gaslini 5, 16147, Genoa, Italy. nicolaruperto@gaslini.org.

Abstract

The Juvenile Arthritis Multidimensional Assessment Report (JAMAR) is a new parent/patient-reported outcome measure that enables a thorough assessment of the disease status in children with juvenile idiopathic arthritis (JIA). We report the results of the cross-cultural adaptation and validation of the parent and patient versions of the JAMAR in the Estonian language. The reading comprehension of the questionnaire was tested in 10 JIA parents and patients. Each participating centre was asked to collect demographic, clinical data and the JAMAR in 100 consecutive JIA patients or all consecutive patients seen in a 6-month period and to administer the JAMAR to 100 healthy children and their parents. The statistical validation phase explored descriptive statistics and the psychometric issues of the JAMAR: the three Likert assumptions, floor/ceiling effects, internal consistency, Cronbach's alpha, interscale correlations, test-retest reliability, and construct validity (convergent and discriminant validity). A total of 110 JIA patients (71.8% oligoarticular, 18.2% RF-negative polyarthritis, 10% other categories) and 98 healthy children were enrolled in one paediatric rheumatology centre. Notably, none of the enrolled JIA patients is affected with systemic JIA. The JAMAR components discriminated healthy subjects from JIA patients, except for the Paediatric Rheumatology Quality of Life (HRQoL) Psychosocial Health (PsH) subscales and for the satisfaction with current health status. All JAMAR components revealed good psychometric performances. In conclusion, the Estonian version of the JAMAR is a valid tool for the assessment of children with JIA and is suitable for use both in routine clinical practice and clinical research.

KEYWORDS:

Disease status; Functional ability; Health-related quality of life; JAMAR; Juvenile idiopathic arthritis

PMID:
29637363
PMCID:
PMC5893665
DOI:
10.1007/s00296-018-3948-x
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center